Bortezomib retreatment is effective in relapsed multiple myeloma patients - real-life clinical practice data.

导出原文传递

翻译打印收藏纠错

第一作者： M,Stork

第一单位： Department of Hematology and Oncology, University Hospital Brno, Brno, Czech Republic.

作者： M,Stork ^[1] ; S,Sevcikova ^[2] ; L,Brozova ^[3] ; I,Spicka ^[4] ; V,Maisnar ^[5] ; J,Minarik ^[6] ; A,Jungova ^[7] ; E,Gregora ^[8] ; R,Velichova ^[3] ; R,Hajek ^[9] ; T,Jelinek ^[9] ; L,Pour ^[1]

作者单位： Department of Hematology and Oncology, University Hospital Brno, Brno, Czech Republic. ^[1] Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic. ^[2] Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic. ^[3] 1st Medical Department, Clinical Department of Hematology of the First Faculty of Medicine and General Teaching Hospital Charles University, Prague, Czech Republic. ^[4] 4th Department of Internal Medicine - Hematology, Faculty Hospital and Charles University in Hradec Kralove, Hradec Kralove, Czech Republic. ^[5] Department of Hemato-Oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic. ^[6] Hematology and Oncology Department , Charles University Hospital Pilsen, Pilsen, Czech Republic. ^[7] Department of Internal Medicine and Hematology, University Hospital Kralovske Vinohrady, Prague, Czech Republic. ^[8] Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine University of Ostrava, Ostrava, Czech Republic. ^[9]